aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
3.240
-0.040 (-1.22%)
At close: May 12, 2025, 4:00 PM
3.320
+0.079 (2.45%)
Pre-market: May 13, 2025, 9:06 AM EDT
aTyr Pharma Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for aTyr Pharma stock ranges from a low of $9.00 to a high of $35. The average price target of $18.6 forecasts a 474.07% increase in the stock price over the next year.
Price Target: $18.60 (+474.07%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 14, 2025.
Analyst Ratings
The average analyst rating for aTyr Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 2 | 3 | 4 | 4 | 4 | 4 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +980.25% | Mar 14, 2025 |
Leerink Partners | Leerink Partners | Buy Initiates $16 | Buy | Initiates | $16 | +393.83% | Feb 18, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jan 6, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +980.25% | Dec 10, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +980.25% | Dec 3, 2024 |
Financial Forecast
Revenue This Year
1.53M
from 235.00K
Increased by 551.06%
Revenue Next Year
34.35M
from 1.53M
Increased by 2,144.84%
EPS This Year
-0.72
from -0.86
EPS Next Year
-0.53
from -0.72
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 12.6M | 123.9M | 240.6M | ||
Avg | 1.5M | 34.3M | 129.5M | ||
Low | n/a | n/a | 19.6M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 5,261.7% | 7,998.0% | 600.4% | ||
Avg | 551.1% | 2,144.8% | 277.0% | ||
Low | - | - | -42.9% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.60 | 0.29 | 1.08 | ||
Avg | -0.72 | -0.53 | 0.15 | ||
Low | -0.90 | -1.23 | -0.81 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.